+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Advanced Drug Delivery Market by Product Type and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 190 Pages
  • December 2021
  • Region: Global
  • Allied Market Research
  • ID: 5548391
The global advanced drug delivery market was valued at $44,029.59 million in 2020, and is estimated to reach $1,95,132.45 million by 2030, growing at a CAGR of 16.0% from 2021 to 2030. Advanced drug delivery is an improved method for delivering the drug molecule to the targeted site in a more controlled manner. Advance drug delivery systems are based on novel drug delivery techniques and utilize the most advanced technologies. They are intended to administer the medicine in a regulated or modulated manner within the tissue or cells, with the goal of providing safe and effective therapy.



The advanced drug delivery system comprises oral, parenteral, pulmonary, transmucosal, transdermal, carrier based systems like nanoparticles, nanospheres, nanocapsules, nanoemulsions, and nano-sized vesicular carriers, such as liposomes, niosomes, dendrimers, and polymeric or lipid-based carriers and other drug delivery systems. These advanced drug delivery technologies have the potential to overcome the limitations of the already existing drugs. Various factors, such as pharmacodynamics, drug toxicity, immunogenicity, bio compatibility, pharmacokinetics, and drug efficacy, are considered while developing advanced drug delivery systems.

The primary goal of adopting advanced drug delivery (ADD) is not only to deliver a biologically active molecule in a regulated way (time, period and releasing rate), but also to keep drug levels in the body within the therapeutic window. Furthermore, the drug can be directed toward a specific organ or tissue (targeted drug delivery).

They assist in the delivery of medication levels in the body by minimizing toxicity and effectively delivering the drug at the intended location of the action. The key benefit of ADD is its flexibility and potential to increase drug bioavailability. Drug therapeutic efficacy and safety profiles can be enhanced by more accurate spatial and temporal placement in the body, resulting in lower dosage frequency. These techniques are being developed to improve the efficacy ratio of currently available medications. The development of advanced drug delivery systems is based on the delivery of drugs at a controlled pace, as well as slow and targeted distribution for onsite drug release and absorption.

The growth of advanced drug delivery market is majorly driven by the rise in the prevalence of chronic diseases. Chronic diseases are described generally as problems that persist a year or longer and need continuous medical treatment, that limit everyday activities, or both.

According to the Center of Disease Control and Prevention (CDC) in 2020, every year, more than 868,000 Americans succumb to heart disease, stroke, or other cardiovascular disorders, accounting for one-third of all deaths in the U.S. 6 out of 10 Americans have at least one chronic condition, and 4 out of 10 have two or more heart, stroke, cancer, or diabetes. These and other chronic diseases are the leading causes of death and disability in the U.S. and they are also a leading driver of healthcare costs. These diseases also take an economic toll, costing $214 billion a year to the health care system and causing $138 billion in lost productivity from premature death alone. They are also major contributors to the country's $3.8 trillion in yearly health-care expenses. Thus, the rise in chronic diseases leads to the surge in demand for advanced drug delivery for safe and effective therapy.

In addition, the market is driven by advancements as well as R&D activities in understanding of human biology and diseases leading to the development of new drugs and biologics. For instance, in December 2019, researchers at the Massachusetts Institute of Technology (MIT) have developed a microneedle platform that uses quantum dots (QD), which are fluorescent microparticles that can deliver vaccines while also invisibly encoding vaccination history in the skin. The quantum dots are made up of nanocrystals that emit near-infrared light that may be detected by a smartphone with a specific sensor. Thus, such developments significantly boost the advanced drug delivery market.

However, rise in the number of drug recalls and drug failures of advanced drug delivery, challenges in nanomedicine based drug delivery are expected to hamper the market growth. For instance, according to the USFDA’s Center for Drug Evaluation and Research (CDER) in 2020 about 53 new molecular entities (NMEs) were approved. Thus, the rise in such drug approvals and innovations further drive the market for designing various advanced drug delivery systems. Furthermore, an increase in R&D spending and surge in healthcare expenditure worldwide, specifically in the developing economies leads to an increased demand for advanced drug delivery products for better efficacy and thus, is a great opportunity for the key players of the market for investment.

The global advanced drug delivery market is segmented on the basis of product type, end user, and region. On the basis of product type, the market is segregated into drug eluting lens, microneedle patch, hydrogel drug delivery and nano carrier. By end user, it is fragmented into hospitals, specialized clinics and others. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific and LAMEA.

The major players profiled in the report are Alnylam Pharmaceuticals Inc., Altaris Capital Partners Llc. (Kindeva Drug Delivery), Bausch Health Companies Inc., (Bausch & Lomb), Biogen Limited, Endo International Plc., Johnson & Johnson (Johnson & Johnson Vision), Micropoint Technologies, Novo Nordisk A/S, Ocular Therapeutix Inc. and Takeda Pharmaceutical Company Limited.


KEY BENEFITS FOR STAKEHOLDERS


  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global advanced drug delivery market to identify the prevailing opportunities.
  • This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Region- & country-wise analysis is provided to understand the market trends and dynamics.



KEY MARKET SEGMENTS




By Product Type


  • Drug eluting lens
  • Microneedle patch
  • Hydrogel drug delivery
  • Nano carrier



By End User


  • Hospitals
  • Specialized clinics
  • Others



By Region


  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA



KEY MARKET PLAYERS


  • Alnylam Pharmaceuticals Inc.
  • Altaris Capital Partners Llc. (Kindeva Drug Delivery)
  • Bausch Health Companies Inc., (Bausch & Lomb)
  • Biogen Limited
  • Endo International Plc.
  • Johnson & Johnson (Johnson & Johnson Vision)
  • Micropoint Technologies
  • Novo Nordisk A/S
  • Ocular Therapeutix Inc.
  • Takeda Pharmaceutical Company Limited
Frequently Asked Questions about the Global Advanced Drug Delivery Market

What is the estimated value of the Global Advanced Drug Delivery Market?

The Global Advanced Drug Delivery Market was estimated to be valued at $44029.59 million in 2020.

What is the growth rate of the Global Advanced Drug Delivery Market?

The growth rate of the Global Advanced Drug Delivery Market is 16.1%, with an estimated value of $195132.45 million by 2030.

What is the forecasted size of the Global Advanced Drug Delivery Market?

The Global Advanced Drug Delivery Market is estimated to be worth $195132.45 million by 2030.

Who are the key companies in the Global Advanced Drug Delivery Market?

Key companies in the Global Advanced Drug Delivery Market include Alnylam Pharmaceuticals Inc., Altaris Capital Partners Llc. (Kindeva Drug Delivery), Bausch Health Companies Inc., (Bausch & Lomb), Biogen Limited, Endo International Plc, Johnson & Johnson (Johnson & Johnson Vision), Micropoint Technologies and Cular Therapeutix Inc..

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profile in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of chronic disorders that require the use of drug delivery systems
3.5.1.2. Surge in healthcare expenditure worldwide
3.5.1.3. Technological advancements and developments made by key players in drug delivery system market
3.5.2. Restraint
3.5.2.1. Rise in number of drug recalls and drug failures
3.5.3. Opportunity
3.5.3.1. Lucrative opportunities in emerging markets
3.6. Impact analysis
3.7. Impact analysis of COVID-19 on the advanced drug delivery market
3.8. Patent analysis, 2019-2021
3.8.1. Patent analysis, by world
3.8.2. Patent analysis, by year
3.9. Clinical trials analysis, 2019-2021
CHAPTER 4: ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Drug eluting lens
4.2.1. Key market trends, growth factors, and opportunities
4.3. Microneedle patch
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Hydrogel drug delivery
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Nano carrier
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: ADVANCED DRUG DELIVERY MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Specialized clinics
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: ADVANCED DRUG DELIVERY MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America advanced drug delivery market, by product type
6.2.3. North America advanced drug delivery market, by end user
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. U.S. advanced drug delivery market, by product type
6.2.4.1.2. U.S. advanced drug delivery market, by end user
6.2.4.2. Canada
6.2.4.2.1. Canada advanced drug delivery market, by product type
6.2.4.2.2. Canada advanced drug delivery market, by end user
6.2.4.3. Mexico
6.2.4.3.1. Mexico advanced drug delivery market, by product type
6.2.4.3.2. Mexico advanced drug delivery market, by end user
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe advanced drug delivery market, by product type
6.3.3. Europe advanced drug delivery market, by end user
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Germany advanced drug delivery market, by product type
6.3.4.1.2. Germany advanced drug delivery market, by end user
6.3.4.2. France
6.3.4.2.1. France advanced drug delivery market, by product type
6.3.4.2.2. France advanced drug delivery market, by end user
6.3.4.3. UK
6.3.4.3.1. UK advanced drug delivery market, by product type
6.3.4.3.2. UK advanced drug delivery market, by end user
6.3.4.4. Italy
6.3.4.4.1. Italy advanced drug delivery market, by product type
6.3.4.4.2. Italy advanced drug delivery market, by end user
6.3.4.5. Spain
6.3.4.5.1. Spain advanced drug delivery market, by product type
6.3.4.5.2. Spain advanced drug delivery market, by end user
6.3.4.6. Rest of Europe
6.3.4.6.1. Rest of Europe advanced drug delivery market, by product type
6.3.4.6.2. Rest of Europe advanced drug delivery market, by end user
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific advanced drug delivery market, by product type
6.4.3. Asia-Pacific advanced drug delivery market, by end user
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Japan advanced drug delivery market, by product type
6.4.4.1.2. Japan advanced drug delivery market, by end user
6.4.4.2. China
6.4.4.2.1. China advanced drug delivery market, by product type
6.4.4.2.2. China advanced drug delivery market, by end user
6.4.4.3. Australia
6.4.4.3.1. Australia advanced drug delivery market, by product type
6.4.4.3.2. Australia advanced drug delivery market, by end user
6.4.4.4. India
6.4.4.4.1. India advanced drug delivery market, by product type
6.4.4.4.2. India advanced drug delivery market, by end user
6.4.4.5. South Korea
6.4.4.5.1. South Korea advanced drug delivery market, by product type
6.4.4.5.2. South Korea advanced drug delivery market, by end user
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Rest of Asia-Pacific advanced drug delivery market, by product type
6.4.4.6.2. Rest of Asia-Pacific advanced drug delivery market, by end user
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA advanced drug delivery market, by product type
6.5.3. LAMEA advanced drug delivery market, by end user
6.5.4. LAMEA advanced drug delivery market, by country
6.5.4.1. Brazil
6.5.4.1.1. Brazil advanced drug delivery market, by product type
6.5.4.1.2. Brazil advanced drug delivery market, by end user
6.5.4.2. Saudi Arabia
6.5.4.2.1. Saudi Arabia advanced drug delivery market, by product type
6.5.4.2.2. Saudi Arabia advanced drug delivery market, by end user
6.5.4.3. South Africa
6.5.4.3.1. South Africa advanced drug delivery market, by product type
6.5.4.3.2. South Africa advanced drug delivery market, by end user
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Rest of LAMEA advanced drug delivery market, by product type
6.5.4.4.2. Rest of LAMEA advanced drug delivery market, by end user
CHAPTER 7: COMPANY PROFILES
7.1. ALNYLAM PHARMACEUTICALS, INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. ALTARIS CAPITAL PARTNERS, LLC. (KINDEVA DRUG DELIVERY)
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.3. BAUSCH HEALTH COMPANIES INC. (BAUSCH & LOMB)
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. BIOGEN LIMITED
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. ENDO INTERNATIONAL PLC.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. JOHNSON & JOHNSON (JOHNSON & JOHNSON VISION)
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. MICROPOINT TECHNOLOGIES PTE LTD.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.8. NOVO NORDISK
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. OCULAR THERAPEUTIX, INC.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Key strategic moves and developments
7.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.10.1. Company overview
7.10.2. Operating business segments
7.10.3. Product portfolio
7.10.4. Business performance
List of Tables
TABLE 01. ADVANCED DRUG DELIVERY MARKET, BY CLINICAL TRIALS
TABLE 02. ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 03. ADVANCED DRUG DELIVERY MARKET FOR MICRONEEDLE PATCH, BY REGION, 2020-2030 ($MILLION)
TABLE 04. ADVANCED DRUG DELIVERY MARKET FOR HYDROGEL DRUG DELIVERY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05. ADVANCED DRUG DELIVERY MARKET FOR NANO CARRIER, BY REGION, 2020-2030 ($MILLION)
TABLE 06. ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 07. ADVANCED DRUG DELIVERY MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 08. ADVANCED DRUG DELIVERY MARKET FOR SPECIALIZED CLINICS, BY REGION, 2020-2030($MILLION)
TABLE 09. ADVANCED DRUG DELIVERY MARKET FOR OTHERS, BY REGION, 2020-2030($MILLION)
TABLE 10. ADVANCED DRUG DELIVERY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11. NORTH AMERICA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 12. NORTH AMERICA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 13. NORTH AMERICA ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 14. U.S. ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 15. U.S. ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 16. CANADA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 17. CANADA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 18. MEXICO ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 19. MEXICO ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 20. EUROPE ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 21. EUROPE ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 22. EUROPE ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 23. GERMANY ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 24. GERMANY ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 25. FRANCE ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 26. FRANCE ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 27. UK ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 28. UK ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 29. ITALY ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 30. ITALY ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 31. SPAIN ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 32. SPAIN ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 33. REST OF EUROPE ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 34. REST OF EUROPE ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 35. ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 36. ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 37. ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 38. JAPAN ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 39. JAPAN ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 40. CHINA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 41. CHINA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 42. AUSTRALIA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 43. AUSTRALIA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 44. INDIA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 45. INDIA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 46. SOUTH KOREA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 47. SOUTH KOREA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 48. REST OF ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 50. LAMEA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 51. LAMEA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 52. LAMEA ADVANCED DRUG DELIVERY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 53. BRAZIL ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 54. BRAZIL ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 55. SAUDI ARABIA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 56. SAUDI ARABIA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 57. SOUTH AFRICA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 58. SOUTH AFRICA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 59. REST OF LAMEA ADVANCED DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
TABLE 60. REST OF LAMEA ADVANCED DRUG DELIVERY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 61. ALNYLAM: COMPANY SNAPSHOT
TABLE 62. ALNYLAM: OPERATING BUSINESS SEGMENTS
TABLE 63. ALNYLAM: PRODUCT PORTFOLIO
TABLE 64. ALNYLAM: KEY DEVELOPMENTS
TABLE 65. ALTARIS: COMPANY SNAPSHOT
TABLE 66. ALTARIS: OPERATING SEGMENTS
TABLE 67. ALTARIS HEALTHCARE: PRODUCT PORTFOLIO
TABLE 68. BAUSCH: COMPANY SNAPSHOT
TABLE 69. BAUSCH: OPERATING SEGMENTS
TABLE 70. BAUSCH: PRODUCT PORTFOLIO
TABLE 71. BIOGEN: COMPANY SNAPSHOT
TABLE 72. BIOGEN: OPERATING SEGMENTS
TABLE 73. BIOGEN: PRODUCT PORTFOLIO
TABLE 74. BIOGEN: KEY DEVELOPMENTS
TABLE 75. ENDO: COMPANY SNAPSHOT
TABLE 76. ENDO: OPERATING BUSINESS SEGMENTS
TABLE 77. ENDO: PRODUCT PORTFOLIO
TABLE 78. JOHNSON: COMPANY SNAPSHOT
TABLE 79. JOHNSON: PRODUCT SEGMENTS
TABLE 80. JOHNSON: PRODUCT PORTFOLIO
TABLE 81. JOHNSON: KEY DEVELOPMENTS
TABLE 82. MICROPOINT: SNAPSHOT
TABLE 83. MICROPOINT: OPERATING SEGMENT
TABLE 84. MICROPOINT: PRODUCT PORTFOLIO
TABLE 85. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 86. NOVO NORDISK: OPERATING SEGMENTS
TABLE 87. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 88. BIOGEN: KEY DEVELOPMENTS
TABLE 89. OCULAR THERAPEUTIX: COMPANY SNAPSHOT
TABLE 90. OCULAR THERAPEUTIX: OPERATING SEGMENTS
TABLE 91. OCULAR THERAPEUTIX: PRODUCT PORTFOLIO
TABLE 92. OCULAR THERAPEUTIX: KEY DEVELOPMENTS
List of Figures
FIGURE 01. GLOBAL ADVANCED DRUG DELIVERY MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2019-2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. HIGH INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. PATENTS REGISTERED/APPROVED IN THE WORLD, 2019-2021
FIGURE 14. PATENTS ANALYSIS, BY YEAR, 2019-2021
FIGURE 15. COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR MICRONEEDLE PATCH, BY COUNTRY, 2020-2030 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR HYDROGEL DRUG DELIVERY, BY COUNTRY, 2020-2030 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR NANO CARRIER, BY COUNTRY, 2020-2030 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY, 2020-2030 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR SPECIALIZED CLINICS, BY COUNTRY, 2020-2030 (%)
FIGURE 20. COMPARATIVE ANALYSIS OF ADVANCED DRUG DELIVERY MARKET FOR OTHERS, BY COUNTRY, 2020-2030 (%)
FIGURE 21. ALNYLAM: NET SALES, 2018-2020 ($MILLION)
FIGURE 22. BAUSCH: NET SALES, 2018-2020 ($MILLION)
FIGURE 23. BAUSCH: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 24. BAUSCH: REVENUE SHARE BY REGION, 2020(%)
FIGURE 25. BIOGEN: NET SALES, 2018-2020 ($MILLION)
FIGURE 26. ENDO: NET SALES, 2018-2020 ($MILLION)
FIGURE 27. ENDO: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 28. JOHNSON: NET SALES, 2018-2020 ($MILLION)
FIGURE 29. JOHNSON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30. JOHNSON: REVENUE SHARE BY REGION, 2020(%)
FIGURE 31. NET SALES, 2018-2020 ($MILLION)
FIGURE 32. NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2020 (%)

Companies Mentioned

  • Alnylam Pharmaceuticals Inc.
  • Altaris Capital Partners Llc. (Kindeva Drug Delivery)
  • Bausch Health Companies Inc.
  • (Bausch & Lomb)
  • Biogen Limited
  • Endo International Plc
  • Johnson & Johnson (Johnson & Johnson Vision)
  • Micropoint Technologies
  • Novo Nordisk A/S
  • Cular Therapeutix Inc.
  • Takeda Pharmaceutical Company Limited.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...